Article
US FDA advisers narrowly back Sarepta's Duchenne gene therapy for accelerated approval
Rating:
0.0
Views:
63
Likes:
1
Library:
1
Advisers to the U.S. Food and Drug Administration on Friday narrowly recommended that the agency grant accelerated approval to Sarepta Therapeutics Inc's first-of-its-kind gene therapy for Duchenne muscular dystrophy (DMD).
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value